The stock of Insmed Incorporated (NASDAQ:INSM) is a huge mover today! About 128,633 shares traded hands. Insmed Incorporated (NASDAQ:INSM) has risen 18.26% since March 9, 2016 and is uptrending. It has outperformed by 10.85% the S&P500.
The move comes after 6 months negative chart setup for the $836.18M company. It was reported on Oct, 12 by Barchart.com. We have $12.69 PT which if reached, will make NASDAQ:INSM worth $75.26 million less.
Analysts await Insmed Incorporated (NASDAQ:INSM) to report earnings on November, 4. They expect $-0.57 EPS, down 14.00% or $0.07 from last year’s $-0.5 per share. After $-0.59 actual EPS reported by Insmed Incorporated for the previous quarter, Wall Street now forecasts -3.39% EPS growth.
Insmed Incorporated (NASDAQ:INSM) Ratings Coverage
Out of 6 analysts covering Insmed (NASDAQ:INSM), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. Insmed has been the topic of 8 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Citigroup maintained it with “Neutral” rating and $13 target price in Wednesday, March 16 report. The stock has “Buy” rating given by Zacks on Friday, September 4. The stock has “Buy” rating given by H.C. Wainwright on Tuesday, October 6. The stock of Insmed Incorporated (NASDAQ:INSM) earned “Hold” rating by Zacks on Thursday, August 20. Stifel Nicolaus initiated the stock with “Buy” rating in Tuesday, March 15 report. The firm earned “Hold” rating on Monday, August 10 by Zacks. The firm has “Neutral” rating given on Monday, November 9 by UBS.
According to Zacks Investment Research, “Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company’s inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.”
Insitutional Activity: The institutional sentiment increased to 1.65 in 2016 Q2. Its up 0.69, from 0.96 in 2016Q1. The ratio increased, as 11 funds sold all Insmed Incorporated shares owned while 23 reduced positions. 17 funds bought stakes while 39 increased positions. They now own 55.48 million shares or 0.92% less from 56.00 million shares in 2016Q1.
The Minnesota-based Us Natl Bank De has invested 0% in Insmed Incorporated (NASDAQ:INSM). Highbridge Cap Ltd Com accumulated 0.01% or 51,372 shares. Bnp Paribas Arbitrage Sa accumulated 2,408 shares or 0% of the stock. Moreover, Citigroup has 0% invested in Insmed Incorporated (NASDAQ:INSM) for 207,280 shares. Blackrock Inc holds 5,904 shares or 0% of its portfolio. Los Angeles Capital Equity reported 33,150 shares or 0% of all its holdings. Janus Capital Mgmt Limited Liability Corporation owns 2.85 million shares or 0.02% of their US portfolio. Manufacturers Life The holds 0% of its portfolio in Insmed Incorporated (NASDAQ:INSM) for 43,590 shares. Rhumbline Advisers has 0% invested in the company for 67,561 shares. Teacher Retirement Of Texas accumulated 0% or 8,286 shares. International Grp Inc Inc, a New York-based fund reported 35,648 shares. Deutsche Fincl Bank Ag holds 0% of its portfolio in Insmed Incorporated (NASDAQ:INSM) for 529,650 shares. Moreover, Legal And General Grp Incorporated Public Limited Company has 0% invested in Insmed Incorporated (NASDAQ:INSM) for 14,289 shares. Jpmorgan Chase And has invested 0% of its portfolio in Insmed Incorporated (NASDAQ:INSM). Commercial Bank Of America Corporation De, a North Carolina-based fund reported 8,775 shares.
More notable recent Insmed Incorporated (NASDAQ:INSM) news were published by: Prnewswire.com which released: “SHAREHOLDER ALERT Rosen Law Firm Reminds Insmed Incorporated Investors of …” on September 07, 2016, also Marketwatch.com with their article: “/quotes/zigman/3870025/realtime” published on December 21, 2009, Fool.com published: “Why Insmed Incorporated Shares Skyrocketed” on June 18, 2014. More interesting news about Insmed Incorporated (NASDAQ:INSM) were released by: Quotes.Wsj.com and their article: “News Insmed Inc.INSM” published on February 14, 2011 as well as Globenewswire.com‘s news article titled: “DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Insmed …” with publication date: September 01, 2016.
INSM Company Profile
Insmed Incorporated, incorporated on March 21, 2013, is a biopharmaceutical company. The Firm operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.